Opendata, web and dolomites

Oralis SIGNED

Oralis, The first oral human insulin treatment for Type 2 Diabetes Mellitus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Oralis project word cloud

Explore the words cloud of the Oralis project. It provides you a very rough idea of what is the project "Oralis" about.

adherence    efficacy    bn    mellitus    generate    glycaemic    billion    thousands    last    opens    lives    region    5000    huge    diabetes    century    commercial    trials    clinical    transform    co    oralis    injected    orally    multiple    insulin    49m    treatment    649    agreements    type    market    solution    181m    2020    annually    overcome    trial    gt    300    capability    share    levels    first    injecting    oramed    49    stigma    sufficient    prognosis    life    therapies    concentration    hundreds    worth    paradigm    bgl    instrument    daily    415m    patient    creation    caring    bioavailable    longer    lifespans    global    demonstrated    revenue    trade    harsh    blood    gastrointestinal    newest    globally    considerable    injections    people    quality    social    commercialise    proven    protects    morbidities    pain    t2dm    liver    glucose    confirm    created    disease    eventual    options    claim    pod    finalise    sme    individuals    pharmaceuticals    patients    prevention    tract    protein    estimation    burden    61    est    oral    injectable    doses   

Project "Oralis" data sheet

The following table provides information about the project.

Coordinator
ORAMED LTD 

Organization address
address: ELZA ST 2
city: JERUSALEM
postcode: 9370648
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ORAMED LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Type 2 Diabetes Mellitus (T2DM) affects 415M people globally, 49M of them within Europe. Caring for these individuals costs Europe €181M billion annually. However, more needs to be done as T2DM and its related co-morbidities claim hundreds of thousands of lives each year in the region. The early control of blood glucose levels (BGL) is the key to the prevention of the disease, and longer lifespans with better prognosis and higher quality of life for T2DM patients. The last century has seen considerable development in T2DM treatment, but the eventual solution to control BGL for many patients are multiple daily insulin injections. This has created a huge global market to be worth €49 billion (est. 2020). The pain, social stigma, and burden associated with injecting insulin contribute to a non-adherence to treatment that has been estimated to be as high as 61%, at a cost 9,649€ per patient per year. Oramed Pharmaceuticals (Oramed) will transform this paradigm with its POD™ technology. It protects protein therapies like insulin from the harsh conditions in the gastrointestinal tract, allowing then to be taken orally. This opens a way into oral insulin treatment to overcome many of the issues contributing to non-adherence of injected insulin treatment in T2DM patients. Using POD™ technology Oramed has produced the first oral insulin and demonstrated its efficacy in Phase II clinical trials with >300 patients and >5000 doses. We have proven oralis capability to deliver to the liver bioavailable insulin at sufficient concentration to produce significant glucose control in all glycaemic parameters in T2DM patients. Through the SME instrument Oramed will finalise the Phase III clinical trial to confirm the efficacy of oralis for glycaemic control in T2DM patients. We have already reach commercial agreements to commercialise oralis. Our estimation is to generate a similar revenue creation and market share as the newest injectable insulin options of €1.7 bn in 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORALIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORALIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

polyBioMetal (2019)

Polymer Biotechnological Metallization

Read More  

NextGen (2020)

Industrial breakthrough of plasma deposited functional Nanocoatings for Filtration Applications

Read More  

EHS (2019)

Thermo-adjustable endoscope heater system to solve problems of fogging during surgical interventions

Read More